In response to speculation in a national newspaper, listed biopharmaceutical company GroPep Limited (ASX: GRO) announced today that ethics committee approval has been received to conduct a clinical research study as part of the ongoing development of its Recurrent Miscarriage project (PV903). The ethics approval is subject to a number of conditions.

The study aims to characterise immune cell populations from the cervix of healthy women as a basis for further studies that will investigate the effect of PV903 in a Phase I clinical trial, planned for 2006.

GroPep will continue to keep the market updated as further information becomes available on the status of the PV903 project.

GroPep is a world leader in the development, manufacture and commercialisation of biologically active proteins for cell culture and biomedical research. The Company has an active biopharmaceutical development program that establishes proof of concept for products in humans and partners the later stages of product development and marketing with major pharmaceutical companies. GroPep is listed on the Australian Stock Exchange Limited (ASX code: GRO).

'"/>

Contact: Tony Mitchell
investorrelations@gropep.com.au
61-883-547-700
Research Australia
14-Jul-2005

Page: 1
Related medicine news :

1. Recurrent melanoma may be more common than previously thought
2. Underweight women at greater risk of miscarriage
3. Easing the anxiety of pregnancy after miscarriage
4. Test project of patient-centered medical home model endorsed by American College of Physicians
5. Spanish project AmIVital creates intelligent communication devices for elderly and disabled people
6. Healthy schools project gets an A
7. New project to analyze why Polycystic Ovary Syndrome and insulin resistance are so closely linked
8. Liverpool launches 20 million project to develop medicines for children
9. New family health history projects focus on Alaska Native, Appalachian communities
10. ESSP launches project on the effects of global environmental change on human health
11. Global Environmental Change and Human Health: New project launched at GEC Conference in Beijing